盐酸缬更昔洛韦片可以治什么？

The tablet, developed by Roche, is the first oral anti-cytomegalovirus infection drug for the treatment of retinitis. Valganciclovir hydrochloride is also approved for the prevention of cytomegalovirus infection after bone marrow, heart, liver, lung and other transplant surgeries. The general course of treatment is 3-6 months. CMV retinitis is a common syndrome that threatens the vision of AIDS patients and bone marrow and organ (liver, kidney, heart, etc.) transplant patients. Ganciclovir has good efficacy in treating cytomegalovirus infection, but its oral bioavailability is very low (6%~9%) and it can only be injected intravenously. CMV infection usually requires long-term maintenance treatment after induction therapy. Intravenous injection is used for long-term treatment, which is inconvenient and difficult for patients to accept. Valganciclovir hydrochloride is the prodrug of ganciclovir. Oral administration can achieve the efficacy of injected ganciclovir and is suitable for long-term treatment of cytomegalovirus infection.

Valganciclovir hydrochloride tablets are administered orally and should be taken with food. Valganciclovir hydrochloride tablets can be rapidly converted into ganciclovir in large amounts. The bioavailability of valganciclovir hydrochloride tablets as measured by ganciclovir is 10 times higher than that of ganciclovir capsules, so the dosage and usage instructions of valganciclovir hydrochloride tablets described below should be strictly followed.

Induction therapy of CMV retinitis: For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity.

Maintenance treatment of CMV retinitis: After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis.

Prevention of CMV infection in transplant patients: For patients who have received solid organ transplants, the recommended dosage is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.